Brussels, 14 November 2025 - EuropaBio welcomes Vial as its newest member.

Founded in 2020 in San Francisco, Vial is reimagining drug development to help bring better therapies to patients faster. The company has raised over $100 million from leading investors.

Vial aims to increase the pace and probability of success for innovative therapies by applying technology and innovation at every steps of the drug development process— from computationally designed therapeutics to clinical trial execution. 

In joining EuropaBio, Vial looks forward to contributing practical experience as an innovation‑driven biotech, especially on topics such as scaling clinical trial capacity in Europe, strengthening competitiveness, and advancing next‑generation R&D approaches to ensure therapies are developed safely and quickly.

Dr. Claire Skentelbery, Director General of EuropaBio, said: “Vial will be an outstanding member of EuropaBio — bringing fast‑paced innovation towards patients and looking to European integration. We will work with Vial to support their growth and also use their pipeline development as an example of how to accelerate novel therapies.”

Paolo Mastrangelo, Chief Corporate Affairs Officer at Vial, said: "Europe has the talent, the science, and the regulatory leadership to be a beacon for breakthrough drug development. We're excited to join EuropaBio and work with partners across the continent to bring better, safer therapies to patients as quickly as possible."

For more information, please visit vial.com